Overall Survival
FIGURE 3 · Panel _A_
Panel _A_ 是同一 FIGURE 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
George Lau, Bruno Sangro, Ann-Lii Cheng, Masatoshi Kudo, Robin Kate Kelley, Won Young Tak, Antonio Gasbarrini, Maria Reig, Ho Yeong Lim, David Tougeron, Enrico N De Toni, Vincent C Tam, Kabir Mody, Jun Gong, Oxana V Crysler, Wattana Sukeepaisarnjaroen, Oleg Lipatov, Manabu Morimoto, Isabelle Archambeaud, Valentina Burgio, Le Thi Tuyet Phuong, Yee Chao, Jean-Marie Peron, Marie-Luise Berres, Yoo-Joung Ko, Di Ran, Mallory Makowsky, Alejandra Negro, Ghassan K Abou-Alfa
Hepatology 83(3) 484-496
BACKGROUND AND AIMS: In the global phase III HIMALAYA study in unresectable HCC, STRIDE significantly improved overall survival (OS) versus sorafenib; durvalumab was noninferior to sorafenib. Immune checkpoint inhibitor studies have shown an association between the occurrence of immune-mediated adverse events (imAEs) and improved OS. We assessed potential associations between the occurrence of imAEs and OS, and temporal patterns of imAEs, in HIMALAYA. APPROACH AND RESULTS: OS in participants who did and did not experience imAEs and the frequency and timing of imAEs were assessed for STRIDE and durvalumab in the safety analysis set of HIMALAYA. imAEs occurred in 139/388 (35.8%) and 64/388 (16.5%) participants with STRIDE and durvalumab, respectively; most were low grade. OS HRs (95% CI) in participants who experienced imAEs versus those who did not were 0.73 (0.56-0.95) for STRIDE and 1.14 (0.82-1.57) for durvalumab. The 36-month OS rate (95% CI) for STRIDE was 36.2% (28.1-46.7) and 27.7% (22.4-34.2) in participants who did and did not experience imAEs, respectively. The most common imAE category with STRIDE was endocrine events (16.5%). Most imAEs occurred ≤3 months after treatment initiation. CONCLUSIONS: Participants who experienced imAEs with STRIDE had a numerical improvement in OS versus those who did not, which was not observed for durvalumab. Long-term OS with STRIDE was observed regardless of imAEs. Most imAEs were low grade, manageable, and occurred in the first 3 months after treatment initiation. Results continue to support the benefits of STRIDE in a diverse population that reflects unresectable HCC globally.
1 个 Figure · 2 个 KM 面板
FIGURE 3 Overall survival by immune-mediated adverse event occurrence for (A) STRIDE and (B) durvalumab in the safety analysis set. a OS HRs and 95% CIs were calculated using Cox modeling, with imAEs as a time-varying covariate to properly account for immortal time bias and stratified by macrovascular invasion (yes or no), etiology of liver disease (HBV or HCV or other/nonviral), and Eastern Cooperative Oncology Group performance status (0 or 1) for participants with versus without imAEs of any grade. Adverse events were graded per the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.03. Abbreviations: CI, confidence interval; HR, hazard ratio; imAE, immune-mediated adverse event; OS, overall survival; STRIDE, Single Tremelimumab Regular Interval Durvalumab.
这些图片未产生 KM 曲线结果,不在主页面重复展示。